EXAMINING SCIENTIFIC & TECHNOLOGICAL TRENDS TO ADVANCE PROTEIN & ANTIBODY THERAPEUTICS
Following the successful 2016 meeting, Global Engage is pleased to announce the 3rd Biologics & Biosimilars Congress, which will be held on 6 – 7 March 2017 in Berlin, Germany. The event attracted over 160 attendees last year, and forms part of our successful Drug Discovery series, which includes conferences on synthetic biology, precision medicine, digital pathology and the human microbiome.
As the biologics market continues to evolve within Europe, driven by the innovation of a variety of companies, this event will provide a platform for leaders in the biopharmaceutical industry to present recent advances in their protein and antibody therapeutics. The speaker panel will examine a variety of areas in the field of biological drugs, with a particular focus on ADC’s and cancer immunotherapy.
Attracting industry, regulatory & academic experts working in all areas of protein and antibody research, the 3rd Biologics Congress will offer an opportunity for you to take home cutting edge strategies, case study examples, regulatory guidelines to allow you to keep abreast of this dynamic field. This will be achieved through a vibrant exhibition room full of technology providers showcasing their solutions, networking breaks, expert-led case study presentations and incisive panel discussions, divided over four tracks.